Lothar Krinke

Lothar Krinke serves as an Adjunct Assistant Professor at West Virginia University School of Medicine with dual appointments in the Department of Neuroscience and the Rockefeller Neuroscience Institute. He concurrently holds executive leadership as CEO of Magstim Inc., a transcranial magnetic stimulation technology company, and serves on the Board of the UCLA Brain Mapping Medical Research Organization, demonstrating significant integration of academic research with industry innovation in neuromodulation.

His educational foundation includes:

• PhD in Molecular Biology from the University at Albany, State University of New York

Dr. Krinke's research program spans two distinct yet complementary domains: contemporary neuromodulation therapies and foundational molecular biology. His current work focuses on advancing transcranial magnetic stimulation (TMS) technology, particularly navigated TMS systems for substance abuse disorders, chronic pain, OCD, and dementia. He actively pursues closed-loop TMS development using neurophysiological biomarkers for patient stratification. His historical research contributions center on RNA-mediated gene regulation mechanisms in bacteriophage lambda, establishing expertise that bridges molecular neuroscience and clinical applications.

Analysis of his publication record reveals a clear evolution from molecular biology (1987-1991) to clinical neuromodulation (2016-2022). Recent work emphasizes collaborative, interdisciplinary approaches to psychiatric neurosurgery and neuromodulation technology development, with strong representation in consensus-building initiatives like the Deep Brain Stimulation Think Tank. His research consistently addresses translational challenges in moving neuromodulation from laboratory to clinical practice.

No scientific awards or fellowships are documented in the available materials.

While specific student mentorship details are not provided, Dr. Krinke's leadership roles indicate significant involvement in research direction and team building. His position as CEO of Magstim Inc. suggests substantial engagement with research commercialization and technology development funding, though specific grant details are not disclosed in the source material.

Dr. Krinke's primary research infrastructure includes Magstim Inc., where he drives TMS technology innovation, and the UCLA Brain Mapping Medical Research Organization, facilitating large-scale neuroimaging collaborations. His work environment integrates academic neuroscience departments with industry R&D, creating a unique ecosystem for accelerating neuromodulation therapies from concept to clinical implementation.